Abstract
The Aspergillus genus of fungi is associated with a broad range of diseases, from severe invasive infections in immunocompromised hosts, to semi-invasive, to chronic disease. Invasive aspergillosis in particular constitutes the most common fungal infection among hematopoietic stem cell transplant (HSCT) recipients and the second-most common fungal infection among solid organ transplant recipients (1), with associated mortality rates that exceed 50% (1,2). The new IDSA guidelines (3) provide a valuable tool concerning prevention, diagnosis and management of these diseases, building upon the previous version (4), with the incorporation of new clinical data. Thus, they provide a useful, up-to-date scaffold to assist in clinical decision-making.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
